Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.
暂无分享,去创建一个
Jacqueline Shields | J. Kaplan | William M Siders | Kristin L Vergilis | Carrie Johnson | Johanne M Kaplan | W. Siders | J. Shields | K. Vergilis | Carrie Johnson
[1] D. Klatzmann,et al. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. , 2001, Cancer research.
[2] S. Rosenberg,et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. , 1997, Journal of immunotherapy.
[3] R. Noelle,et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. , 2001, Cancer research.
[4] S. Rosenberg,et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.
[5] P. Walden. Hybrid cell vaccination for cancer immunotherapy. , 2000, Advances in experimental medicine and biology.
[6] J. Mulé,et al. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. , 2001, Cancer research.
[7] T. Ohno,et al. Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[8] G. Müller,et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. , 1998, British journal of urology.
[9] W. Sterry,et al. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma , 2000, International journal of cancer.
[10] A. Gross,et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.
[11] S. Rosenberg,et al. Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.
[12] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[13] D. Kufe,et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.
[14] Wei Chen,et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.
[15] L. Zitvogel,et al. Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.
[16] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[17] B. Seliger,et al. TAP off--tumors on. , 1997, Immunology today.
[18] S. Wojtowicz-Praga. Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy , 1997, Journal of immunotherapy.
[19] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.
[20] M. Bevan,et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.
[21] D. Kufe,et al. Induction of Antitumor Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA1 , 2000, The Journal of Immunology.
[22] W. Morrow,et al. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model , 1998, Gene Therapy.
[23] R. Steinman,et al. The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.
[24] P. Walden,et al. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes , 1994, Cancer Immunology, Immunotherapy.
[25] J. Kaplan,et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.
[26] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[27] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[28] Simon C Watkins,et al. Maturation and Trafficking of Monocyte-Derived Dendritic Cells in Monkeys: Implications for Dendritic Cell-Based Vaccines1 , 2000, The Journal of Immunology.
[29] P. De Baetselier,et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity , 1998, International journal of cancer.
[30] A. Dalgleish,et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. , 2000, Biochimica et biophysica acta.
[31] T. Wagner,et al. A Rapid, Novel Strategy to Induce Tumor Cell–Specific Cytotoxic T Lymphocyte Responses Using Instant Dendritomas , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[32] J. Bryant,et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.